Stem cell specialist Miracell to unveil ‘Smart Mcell 2’ bio-stem cell extraction system after participating in European expos
Stem cell specialist Miracell touring Europe after participating in the European Expo: “To unveil ‘Smart Mcell 2,’ a bio-stem cell extraction system.” G.ECONOMY (G Economy) Reporter Kang Min-ji | Stem cell specialist Miracell is conducting a global marketing campaign from April 27th to May 16th, touring Italy, Jordan, Qatar, Kuwait, Saudi Arabia, and Dubai. The company participated in the ‘2022 COSMOPROF Worldwide Bologna,’ the world’s oldest and largest cosmetics and beauty fair, held in Italy. The fair, in its 53rd year, ran from April 29th to May 2nd and attracted over 300,000 visitors from 140 countries. Following this, the company visited Jordan, Qatar, Kuwait, Saudi Arabia, and Dubai to sign contracts and discuss matters with Middle Eastern buyers it met at the Dubai International Medical Devices Exhibition in January. At these exhibitions, the company showcased its cutting-edge bio-stem cell extraction system, “SMART M-CELL2,” developed with domestic technology, and is currently in contract negotiations. Through its membership in the Cellpia Global Platform (CGP), Miracell is actively networking with medical professionals at hospitals and clinics both domestically and internationally, sharing its specialized stem cell medical technology.CGP provides education, technology transfer, medical system setup, and marketing services to hospitals both domestically and internationally to ensure safe stem cell regenerative medicine treatments. Shin Hyun-soon, CEO of Miracell, stated, “Following Europe and the Middle East, we plan to continue Miracell’s legacy in South America. The Nordic countries that participated in the exhibition also showed great interest.” He added, “We are currently in the process of obtaining patents in over 40 countries around the world, including the U.S. Food and Drug Administration (FDA), so our future sales outlook is bright.”
Miracell Participates in Paris Expo, After Italy and the Middle East, to Expand Overseas Markets
Miracell Expands Overseas Markets, Participating in the Paris Expo, After Visiting Italy and the Middle East “Introducing the bio stem cell extraction system ‘Smart Mcell 2’ to the world! [Edaily Reporter Lee Soon-yong] Stem cell specialist Miracell (CEO Shin Hyun-soon) is accelerating the export of its self-developed “Bio Stem Cell Extraction System.” Miracell’s Smart Mcell 2, a system capable of selectively collecting large quantities of stem cells, received certification as a “New Health Technology” from the Ministry of Health and Welfare in February of last year. Capable of isolating and extracting approximately 2.9 billion cells per session in less than an hour, this cutting-edge bio-device, equipped with special LEDs to enhance cell activity, is being used for therapeutic purposes at major hospitals in Korea. Miracell will be attending the “IMCAS World Congress 2022,” a medical device exhibition, held in Paris, France, from June 3rd to 5th, to connect with global buyers with the Smart Mcell 2. To promote its bio-stem cell extraction system, “Smart M-Cell 2,” globally, Miracell participated in the International Medical Devices Fair 2022 in São Paulo, Brazil (May 17-20) and Cosmoprof Bologna 2022 in Italy (April 28-May 1),receiving favorable reviews from the bio industry and healthcare professionals. “Smart M-Cell 2” is also poised to enter the Middle East market. CEO Shin Hyun-soon visited Jordan, Qatar, Kuwait, Saudi Arabia, and Dubai in April and May to negotiate contracts with buyers he met at the Dubai International Medical Devices Fair in January, and has achieved significant results with a series of contracts. Miracell, through its membership in the Cellpia Global Platform (CGP), has built an organic network with medical professionals at domestic and international hospitals and clinics, sharing its specialized stem cell medical technology. CGP provides education, technology transfer, medical system setup, and marketing to hospitals both domestically and internationally, ensuring safe stem cell regenerative medicine treatments. CEO Shin Hyun-soon stated, “Currently, Smart Mcell 2 has received European CE certification and is in the process of obtaining US FDA approval. We anticipate that this technology, which meets international standards, will enable us to conquer the global market.”
Miracell to Unveil ‘SMART M-Cell2’ Stem Cell Centrifuge at BIO KOREA 2022… “Increasing Accessibility to Stem Cell Therapy!”
Miracell unveils stem cell centrifuge ‘SMART M-Cell2’ at BIO KOREA 2022… “We will increase accessibility to stem cell treatment!” Miracell Co., Ltd. (CEO Shin Hyun-soon) participated in ‘BIO KOREA 2022’ held at COEX in Seoul from Wednesday, May 11th to Friday, May 13th. Founded in 1986, Miracell manufactures medical devices, food products, cosmetics, and actively engages in wholesale, retail, trade, and import/export operations. Furthermore, Miracell has accumulated expertise and know-how through continuous research and development in stem cells, and is introducing various technologies and products to further specialize in stem cell therapy. Recognized for its outstanding stem cell research, Miracell won the Medical Korea Grand Prize in 2012. The following year, in 2013, it registered autologous stem cell therapy for critical limb ischemia (Buerger’s disease, diabetic foot, etc.) as a new medical technology. Since then, it has listed a variety of stem cell treatments for acute myocardial infarction, osteoarthritis, and osteoarthritis, as well as stem cell cosmetics and medical devices. At this exhibition, Miracell introduced the “SMART M-Cell 2,” a bone marrow and blood stem cell collection medical device. Designated as an innovative medical device and certified as a New Excellent Technology (NET), this stem cell extraction device extracts blood or bone marrow and centrifuges it to selectively isolate cells. The cells collected through this process can be used for personalized treatments for target patients. Miracell’s Smart M-Cell 2 boasts the advantage of handling larger volumes of bone marrow or blood than commonly used autologous platelet-rich plasma (PRP) therapy devices. Officials explained that this naturally increases the amount of effective cells obtained from a single centrifugation process. A Miracell representative stated, “Currently, Smart Mcell 2 has received European CE certification and is in the process of obtaining US FDA approval.” “With technology that meets international standards, we expect to be able to target the global market. We also believe this will significantly transform the domestic market, which has been heavily reliant on imported products.” They continued, “The public often perceives stem cell therapy as a treatment for the wealthy due to its high cost. Therefore, we aim to create an environment and atmosphere where anyone can receive stem cell therapy at a reasonable cost through our products. We will also continue to conduct research and development to further expand the scope of stem cell therapy.” Meanwhile, ‘BIO KOREA 2022,’ now in its 17th year, was hosted by the Korea Health Industry Development Institute and North Chungcheong Province. BIO KOREA, with the participation of world-renowned scholars and business experts every year, has solidified its position as Korea’s leading international biohealth convention. BIO KOREA 2022, which brings together domestic and international companies in the bio, pharmaceutical, medical device, cosmetics, and food industries, as well as interested companies and organizations from consulting, academia, and related organizations, featured diverse programs including conferences, business forums, exhibitions, and investment fairs.
Miracell and Severance Hospital Sign Clinical Trial Agreement for Stem Cell Therapy to Treat Brain DiseaseName Admin Date 2022-03-22 Hits 894
Miracell and Severance Hospital Sign Clinical Trial Agreement for Stem Cell Treatment of Brain Disease [Edaily Reporter Lee Soon-yong] Stem cell specialist Miracell Co., Ltd. announced on the 22nd that it has signed a Memorandum of Understanding (MOU) with Severance Hospital. Recently, Miracell signed a memorandum of understanding (MOU) with Severance Hospital at its Yeoksam-dong headquarters to promote medical innovation research and development and advanced regenerative biotechnology. The first project will be to investigate the effectiveness of blood stem cells in treating central nervous system and cardiovascular diseases using Miracell’s technology. The research team from the Department of Neurology at Severance Hospital in Sinchon stated, “80-90% of cerebral infarctions occur when a small blood clot ruptures in the carotid artery, causing it to enter the bloodstream. This clot then grows and becomes a thrombus, suddenly occluding the cerebral blood vessel.” Therefore, they stated, “We intend to investigate the effects of administering stem cells and other components isolated from patients’ blood using Miracell’s stem cell extraction system on the regression of atherosclerotic plaques.” The purpose of this clinical study is to verify the efficacy of stem cell therapy in models of atherosclerosis and vascular dementia. The goal is to examine the therapeutic effects of non-surgical stem cell administration in patients with mild cognitive impairment and dementia. After drawing 240 cc of venous blood from the patient, Miracell’s advanced stem cell extraction system, “Smart M-cell2,” was used to isolate and concentrate stem cells with minimal manipulation. The cells, along with growth factors, immune cells, platelets, signaling molecules, and mannitol, which enhances blood-brain barrier permeability, are then administered intravenously. Miracell CEO Shin Hyun-soon stated, “This joint research project, conducted through an MOU with Severance Hospital, a leading medical institution in Korea, will contribute to the advancement of advanced regenerative biotechnology and the popularization of stem cell therapy. Through this research, we hope to optimize the effectiveness of stem cells in improving blood circulation and tissue regeneration, thereby increasing the cure rate for brain diseases.” The Miracell stem cell system has already been certified by the Ministry of Health and Welfare as a novel medical technology for the treatment of acute myocardial infarction (coronary angioplasty, coronary artery bypass grafting), critical limb ischemia, and cartilage defects. It is actively being used in the treatment of these conditions. Furthermore, following the European Union’s CE marking in 2020, it received NET (New Health Technology No. 179) approval in 2021, and is currently in the process of obtaining FDA approval. Miracell’s Smart Mcell 2, used in this clinical trial, is a cutting-edge cell extraction system that has been certified as an “Innovative Product” by the Ministry of Health and Welfare and can be supplied to national hospitals and other government institutions through the Public Procurement Service. Through this agreement, the two organizations will collaborate to develop specialized stem cell therapies for central nervous system and cardiovascular diseases, based on the identification of unmet clinical needs. Furthermore, they plan to exchange technical information, host joint academic conferences and seminars, and share research facilities and equipment.
[NEWS] Miracell to advance into Middle East with stem cell extraction technology
Miracell to advance into Middle East with stem cell extraction technology Miracell, a Korean stem cell therapy company, is prepping to enterthe Middle East market after successful penetration in Europe. The company’s afternoons are entirely devoted to videoconferencing with potential buyersin the Middle East, the company’s chief executive Shin Hyun-soon told Maeil Business Newspaperin a recent interview. Miracell founded 2009 has been dedicated to stem cell therapy, cell banking,medical devices and cosmetics business. Stem cells need to be separated and concentrated as the amount extracted from the human body isvery small. Miracell developed a stem cell extraction device with its own technology and receivednew health technology certification in February last year from the Ministry of Health and Welfare. The company’s Smart M-CELL2 is a regenerative medical device designed to extracta large amount of automatically separated stem cells by concentrating cellsfrom whole blood and bone marrow. It can separate and extract about 2.9 billion cells per time within one hour. These cells are being usedfor treatment purposes in major hospitals in Korea. Anticipation is high for the Smart M-CELL2as the device was superior to Smart PReP2 from Harvard University’s immunology research centerin terms of cell viability and recovery rate in clinical trials conducted by Seoul Medical Science Instituteand Seoul National University Bundang Hospital, Shin said. The company is exploring strategic partnerships and business growth opportunities with fast-trackentry into the global market after the device was well received during Arab Health 2022 heldin Dubai early this year. The company is also aiming to develop a mobile app that will serve asa global platform connecting patients and hospitals for stem cell therapy around the world. By Yoo Joo-yeon and Minu Kim ▶ https://pulsenews.co.kr/view.php?year=2022&no=213850
Miracell Receives Minister of Trade, Industry and Energy Award for New Medical Technology Research and Development
Miracell Receives Minister of Trade, Industry and Energy Award for New Medical Technology Research and Development “Smart Mcell 2″ Development Achievements Highly Recognized” Miracell CEO Shin Hyun-soon received a commendation from the Minister of Trade, Industry and Energy at the opening ceremony of “KIMES 2022” held at COEX on March 10th in recognition of his contributions to the advancement of the medical device industry through research and development of new medical technologies. KIMES annually recognizes and awards individuals who have contributed to the advancement of the medical device industry and exports, in an effort to elevate the standards of international medical device and hospital equipment exhibitions and to promote the growth of the medical device industry. This year, Miracell was selected as the recipient of the Minister of Trade, Industry and Energy commendation for its “Smart M-cell 2,” a cutting-edge stem cell extraction system, in recognition of its achievements in new medical technology research and development. The “Smart M-cell 2,” a system capable of selective stem cell collection, is a regenerative medical device that extracts large quantities of automatically separated stem cells from bone marrow and blood extracted from the body through centrifugation with minimal manipulation. Miracell received NET New Health Technology certification from the Ministry of Health and Welfare for its Smart Mcell 2 and was selected as a national representative for innovative companies in the health/diagnosis sector. Miracell’s stem cell extraction system, already used for therapeutic purposes at major hospitals in Korea, recently received “Innovative Product Designation Certification” from the government,enabling it to be supplied to national and public hospitals and other government institutions through the Public Procurement Service. Miracell is the first company in Korea to have four new medical technology assessments from the Ministry of Health and Welfare,including autologous stem cell therapy for cartilage defects, acute myocardial infarction, and diabetic critical limb ischemia. It is a stem cell specialist company with numerous patent applications in 15 countries, including two in the EU. Miracell CEO Shin Hyun-soon said in his acceptance speech, “For over 15 years, we have dedicated ourselves to researching stem cells and developing a system capable of selectively isolating them for therapeutic use. To enhance cell viability, recovery rates, and cell health, we were the first in the world to incorporate an LED laser. The results were very successful. I am delighted that the government has recognized our outstanding technology.” CEO Shin continued, “In an aging society, personalized disease prediction, prevention, healthcare, and even disease treatment are becoming increasingly important. Therefore, we will do our best to promote Miracell’s unique technology in the global bio-regenerative market.” Following its participation in the Arab Health Fair in February, Miracell plans to promote the Smart Mcell 2 in the first half of the year by participating in booths at the 2022 Cosmoprof Bologna, Italy (April 29-May 2) and the São Paulo Medical Device Exhibition (May 17-20). Meanwhile, Miracell, which also operates a stem cell research center, is also focusing its efforts on stem cell-based treatments for intractable diseases, such as early-stage dementia, in collaboration with domestic university hospitals.
Miracell to Participate in KIMES 2022 with Advanced Stem Cell Medical Devices
Miracell to Participate in KIMES 2022 with Advanced Stem Cell Medical Devices Extraction of large quantities of stem cells through centrifugation with minimal manipulation Miracell announced on the 6th that it plans to participate in the medical device exhibition “KIMES 2022.” The 37th Korea International Medical & Hospital Equipment Show (KIMES 2022) will be held for four days from the 10th to the 13th,under the theme “KIMES, Where New Hope Begins.” Miracell’s “Smart M-cell 2” is a cutting-edge regenerative medical bio-device that extracts large quantities of stem cells through centrifugation with minimal manipulation,enriched and automatically separated. The company explained that the device, a “bone marrow and blood stem cell extraction device including a centrifuge vessel capable of selective separation,”has received approval from the Ministry of Food and Drug Safety and certification as a new medical technology by the Ministry of Health and Welfare. Stem cells have recently been recognized for their limitless benefits in cartilage defects, pain management, preventive medicine, and holistic healthcare, attracting increasing interest from medical professionals and industry professionals. Miracell’s Cellpia Global Platform (CGP) shares stem cell medical technology through a network of member hospitals and clinics. CGP provides education, technology transfer, medical equipment setup, and marketing to hospitals in Korea and abroad to ensure safer stem cell regenerative medicine treatments. A company representative explained, “Miracell’s CGP hospitals are located in major cities across the country, including Daejeon, Daegu, Gwangju, Ulsan, and Busan, in addition to the Seoul metropolitan area, offering orthopedic, plastic, dermatological, urological, obstetrics and gynecological, and family medicine services.” By Sangjun Ahn ansang@viva100.com
Miracell’s ‘Smart Mcell 2’ Targets the Middle East: Massive Stem Cell Extraction After Blood Concentration
Miracell’s “Smart M-Cell 2” Targets the Middle East: Massive Stem Cell Extraction After Blood Concentration Received Ministry of Health and Welfare “New Health Technology” certificationPerformance demonstrated at Seoul National University Bundang HospitalPraise received at Dubai Medical Equipment Exhibition Miracell, a stem cell specialist, is aggressively targeting the Middle Eastern market following its European expansion. Shin Hyun-soon, CEO of Miracell, recently met with Maeil Business Newspaper at the Miracell headquarters in Yeoksam-dong, Seoul.“Miracell’s cutting-edge bio-stem cell extraction system is receiving enthusiastic responses in the Middle East, including the United Arab Emirates (UAE),” he said. “These afternoons are filled with Zoom meetings with Middle Eastern countries.” Founded in 2009, Miracell’s core businesses include cell storage services, medical device and cosmetic manufacturing, and stem cell therapy. Stem cells are so small that they cannot be used immediately after extraction,needing separation and concentration. Miracell developed its own stem cell extraction device, which received “New Health Technology” certification from the Ministry of Health and Welfare in February of last year. The company’s “Smart M-cell 2” is a regenerative medical device that extracts bone marrow and blood, concentrates them through centrifugation, and then automatically extracts a large amount of isolated stem cells. Approximately 2.9 billion cells can be extracted per session in less than an hour. Equipped with a special LED to enhance cell activity,it is currently being used for therapeutic purposes at major hospitals in Korea. CEO Shin stated, “Smart M-cell 2 has shown clinical trials at the Seoul Institute of Medical Science and Bundang Seoul National University Hospitalto outperform Harvard Medical School’s Immunology Research Institute’s “Smart Prep” in terms of cell viability and recovery rates. Expectations are high.” He added, “Having received an enthusiastic response at the Dubai International Medical Device Exhibition earlier this year,we will actively pursue our global market expansion, including in the Middle East.” CEO Shin is also developing an app to popularize stem cell treatment. CEO Shin explained, “We will create a global platform that connects domestic and international patients with hospitals around the world, making it easier for patients around the world to exchange treatment information.” Reporter Yoo Joo-yeon
Miracell Expands its Middle Eastern Market with “Smart M-Cell 2” Following Europe
Miracell to Target the Middle East with ‘Smart M-Cell 2’ Following Europe Participating in Dubai International Medical Device Exhibition Following its success in the European market, stem cell specialist Miracell (CEO Shin Hyun-soon) is targeting the Arab market. Miracell announced on the 19th that it will participate in the “Dubai International Medical Device Exhibition (Arab Health 2022)” held in Dubai from the 24th to the 27th. The Dubai International Medical Device Exhibition, held in 1976 and now in its 47th year, is the largest medical device exhibition in the Middle East and one of the world’s four largest medical device exhibitions. Last year, it attracted 110,000 attendees from 64 countries. Miracell will showcase its “Smart M-Cell 2,” a “state-of-the-art bio-stem cell extraction system” developed using domestic technology. Furthermore, through membership in the Cellpia Global Platform (CGP), the company has built an organic network with doctors and medical staff at hospitals and clinics both domestically and internationally, sharing specialized stem cell medical technology. CGP provides education, technology transfer, medical system setup, and marketing for safe stem cell regenerative medicine treatments at hospitals both domestically and internationally. CEO Shin Hyun-soon stated, “At an exhibition held in Germany, Miracell secured contracts from buyers who expressed satisfaction with Miracell’s bio-stem cell system, which received European CE certification, and its therapeutic effects for psoriasis and other conditions.” He added, “We will continue our success in Europe in the Middle East and expand globally.” He added, “We are currently pursuing global patents, including those from the FDA, in over 40 countries, so our future sales outlook is bright.”
Miracell Recruiting for Early Mild Dementia Stem Cell Clinical Trial
Miracell Recruiting for Early-Medium Dementia Stem Cell Clinical Trial Stem cell company Miracell (CEO Shin Hyun-soon) announced on the 19th that it will conduct a stem cell clinical trial for dementia with the neurosurgery team at Hanyang University Hospital. The number of young patients with early-onset dementia in their 30s and 40s has been increasing. Since many patients rely solely on medication, Miracell explained that it and the neurosurgery team at Hanyang University Hospital decided to conduct a clinical trial targeting early-onset dementia patients.This trial focuses on managing blood vessels, which are the pathways that supply oxygen and nutrients. Since damage to blood vessels can lead to abnormalities in all brain diseases, CD34+, platelets, cytokines, and VGEF growth factors will be injected directly into the blood vessels, transporting them to the brain. This clinical trial will be conducted under the title “The Effects of Autologous Blood-Derived Stem Cells in Patients with Vascular Dementia (Prospective, Randomized, Controlled Trial).” Accordingly, participants in the clinical trial are currently being recruited for patients with vascular dementia. Vascular dementia is the second most common disease after Alzheimer’s, but currently, there is no clear treatment beyond managing risk factors such as high blood pressure and diabetes. Therefore, this study will selectively isolate cells from the patient’s own blood and inject them safely into the body to assess neurological prognosis, neuroprotective effects, and improvement in dementia symptoms. The stem cell extraction for this study will be conducted under the leadership of the neurosurgery team at Hanyang University Hospital, using the SMART M-CELL2 and BSC regenerative medicine biosystems developed by Miracell.CEO Shin Hyun-soon stated, “Smart M-CELL2 and BSC, which have been approved by the Ministry of Health and Welfare and the Ministry of Food and Drug Safety, have been approved not only in Korea but also in the EU. Using this device, we selectively extract up to 98% of superior biological molecules and cells, and inject them directly into the body through a safe route, eliminating concerns about side effects.” Clinical trial subjects are selected after completing a baseline screening. Patients with early-onset dementia aged 40 to 70 who have had vascular dementia for more than three months, have shown minimal improvement despite current medication, and have not seen any improvement in symptoms.